All In Biotech

Drug Trial Radar · NCT06495229

Study of CM310 in Adolescent Subjects With Atopic Dermatis

A Multicenter, Single Arm, Open Label Study to Evaluate the Safety and Efficacy of CM310 in Adolescent Patients With Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Oct 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Aug 2, 2024

Primary completion

Aug 30, 2026

Study completion Aug 30, 2026

Sponsor

Lead sponsor
Keymed Biosciences Co.LtdIndustry
Sponsor type
Industry
First posted
Jul 10, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, single arm, open label phase 3 study to evaluate the safety and efficacy of CM310 in children patients with moderate-to-severe atopic dermatitis.

Conditions

  • Atopic Dermatitis

Interventions

  • CM310Biological

    Interleukin-4 receptor(IL-4Rα) monoclonal antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse eventsTime frame: up to week 52

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University People's hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.